Currently, Celldex Therapeutics Inc [CLDX] is trading at $20.82, up 3.79%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLDX shares have gain 1.96% over the last week, with a monthly amount drifted -0.43%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on April 28, 2025, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $64. Previously, Morgan Stanley started tracking the stock with Overweight rating on March 20, 2025, and set its price target to $46. On February 13, 2025, UBS initiated with a Buy rating and assigned a price target of $44 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $70 on October 07, 2024. Goldman initiated its recommendation with a Neutral and recommended $45 as its price target on September 30, 2024. Wolfe Research downgraded its rating to Peer Perform for this stock on September 27, 2024. In a note dated June 18, 2024, Stifel initiated an Buy rating and provided a target price of $58 on this stock.
This stock has fluctuated between a low of $14.40 and a high of $47.00 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $20.82 at the most recent close of the market. An investor can expect a potential return of 120.94% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
Trailing Twelve Months sales for Celldex Therapeutics Inc [NASDAQ:CLDX] were 7.56M which represents 345.51% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -28.74%, Pretax Profit Margin comes in at -23.66%, and Net Profit Margin reading is -23.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.23 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.07 points at the first support level, and at 19.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.26, and for the 2nd resistance point, it is at 21.70.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Celldex Therapeutics Inc [NASDAQ:CLDX] is 21.67. Further, the Quick Ratio stands at 21.67, while the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 182.85, the price to book ratio is 1.97.
Transactions by insiders
Recent insider trading involved Marucci Anthony S, PRESIDENT & CEO, that happened on Nov 11 ’24 when 11500.0 shares were purchased.
